

Identification of differentially expressed genes in human lung adenocarcinoma: ERGIC3 as a novel lung cancer-related gene



Mingsong Wu

Department of Cell Biology and Genetics,
Zunyi Medical University, China


Las Vegas 2014.10

Part I 1、Background

1.1 epidemiology of lung cancer




Mortality in lung cancer in selected countries 1950–2006



Jemal et al. Cancer Epidemiology, Biomarkers & Prevention. (2010)

Subtype of lung cancer



New tumor marker of lung cancer
for early diagnosis and treatment

To investigate genetic mechanism
and
new target

1.2 Molecular basis of LC




Figure 1

Histopathological and molecular changes during the pathogenesis of squamous cell carcinoma of the lung with molecular changes commencing at early stages, and a histologically normal respiratory epithelium. There is stepwise molecular and histopathological sequence of events leading to dysplastic and invasive carcinoma stages. LOH, loss of heterozygosity.

1. 3 Suppression subtractive hybridization(SSH)


- cDNA Microarray
- mRNA Differential display, DD
- Representational difference analysis, RDA
- Suppression subtractive hybridization, SSH**

lower false positive, higher specific & sensitive


2、Results

2.1 Construction of AC-associated :

2.1.1 Total RNA & mRNA




total RNA




mRNA

2. 1. 2 Analysis of Rsa I digestion




digestion of double cDNA


2. 1. 3 Ligation efficiency analysis




2. 1. 4 Supression PCR



2. 2 Clone of EST



FSL: 485 up-regulated
RSL: 172 down-regulated



2. 3 Bioinformatic analysis

2. 3. 1 BLAST

表 1. 正向杂交文库中差异表达基因的定义、染色体座位和重复的克隆数

Accession	Definition	Cytoband	Recovery
XM_002345305	Homo sapiens similar to DC48 (LOC100293563)		
NM_002790	proteasome (prosome, macropain) subunit, alpha type, 3	1p13	1
N			


表 2. 反向杂交文库中差异表达基因的定义、染色体座位和重复的克隆数

N	Accession	Definition	Cytoband	Recovery
N	NM_001400	sphingosine-1-phosphate receptor 1 (S1PR1)		
N	NM_002038	interferon, alpha-inducible protein 6 (IFI6)		
XI	NM_173452	ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen) (FCN3)	1p31	1
XI	NM_014624	S100 calcium binding protein A6 (S100A6)	1q21	1
N	NM_001043353	tropomyosin 3 (TPM3)	1q21.2	9
XI	NM_139119	YY1 associated protein 1 (YY1AP1)	1q22	1
	NM_148964	cathepsin E (CTSE)	1q31	2
NM_020216	arginylaminopeptidase (aminopeptidase B) (RNPEP)	1q32	1	
NM_014713	lysosomal protein transmembrane 4 alpha (LAPTM4A)	2p24.1	1	
NM_207328	hypothetical protein LOC150763	2q11.1	1	
NM_004657	serum deprivation response (phosphatidylserine binding protein) (SDPR)	2q32-q33	1	
NM_032495	HOP homeobox (HOPX), transcript variant 1	4q11-q12	2	
NM_001042734	SEC24 family, member B (<i>S. cerevisiae</i>) (SEC24B)	4q25	1	


Gene: 177 (new: 152)
Unknown EST: 44

Gene: 59 (new: 54)
Unknown EST: 10


2. 3. 2 GO Ontology




2. 3. 3 Biocatar pathway RSL



2. 3. 4 Biocatar pathway FSL




2. 4 Sreen of SSH-libraries



Part II 1、Background

- (Endoplasmic reticulum-Golgi intermediate compartment 3, ERGIC3)
- Cycles between the endoplasmic reticulum and Golgi
- II type transmembrane protein, 383 aa, 43.2 kDa






Herzog, et al. 2006

- Mutation: COPII ↓ 25%
 - Accumulation of protein and lipid in ER
- Inhibits ER stress-induced cell death


- **FUNCTION?**
- **TUMOR MARKER**

2、RESULTS


2.1 Expression of ERGIC3 in NSCLC mRNA of ERGIC3



2. 1. 2 Protein of ERGIC3



2.1.3 Protein of ERGIC3




Evaluation of immunohistochemical positivity in lung cancer tissues

Tumour and clinicopathological features	Score			
	-	+	++	+++
Gender				
Male	3/17(17.6)	5/17(29.4)	4/17(33.5)	5/17(29.4)
Female	1/18(5.6)	4/18(22.2)	5/18(27.8)	8/18(44.4)
Histological type*				
AC	0	6/22(27.3)	7/22(31.8)	9/22(40.9)
SCC	4/13(30.8)	3/13(23.1)	2/13(15.4)	4/13(30.8)
TNM stage				
I + II	3/20(15.0)	5/20(25.0)	7/20(35.0)	5/20(25.0)
III + IV	1/15(6.7)	4/15(26.7)	2/15(13.3)	8/15(53.3)
Differentiation*				
Poor	4/11(36.4) *	2/11(18.2) *	1/11(9.1) *	4/11(36.4) *
Well or Moderate	0	7/24(29.2) *	8/24(33.3) *	9/24(37.5) *
Smoking				
No	1/17(5.9)	4/17(23.5)	4/17(23.5)	8/17(47.1)
Yes	3/18(16.7)	5/18(27.8)	5/18(27.8)	5/18(27.8)


Positive rate:88.57%
AC>SCC

Score: -, no staining; +, <30%; ++, 31–60%; +++, >60% positive cells

2. 1. 4 Location of ERGIC3




2. 1. 4 Location of ERGIC3




2.2 Functions of ERGIC3 in lung cancer


ERGIC3 promotes cellular growth



2. 2. 2 ERGIC3 promotes cellular migration



2.2.3 Stable overexpression of ERGIC3 promotes cellular migration



3、Summary

- Library of differentially expressed genes in lung cancer.
- Potential targets for diagnostic & therapeutic usage.
- Two lung cancer associated genes.
- ERGIC3 may be a new biomarker for lung cancer.
- ERGIC3 may be a novel candidate oncogen for lung cancer.

Thank you!